Table 1

Screening characteristics of 253 IAR from FPC families

ParameterTotal cohort
(n=253)
High-risk IAR
(n=96)
Moderate-risk IAR
(n=140)
IAR with BRCA1/2, PALB2 mutation
(n=17)
Median age (range), years at screening start48 (25–81)48 (28–71)48 (26–81)46 (25–70)
Gender (M/F)115/13843/5368/724/13
Examination visits median/range853 3 (1–11)339 3 (1–11)461 3 (1–11)53 2 (1–9)
Number MRI/MRCP median/range813 2 (1–11)327 3 (1–11)433 2 (1–11)53 2 (1–9)
Number EUS median/range450 1 (0–8)139 1 (0–7)280 1 (0–8)31 1 (1–4)
Pancreatic lesions134 (52.9%)50 (52.1%)74 (52.8%)10 (59%)
IAR with significant lesions*6 (2%)3 (3.1%)2 (1.4%)1 (5.9%)
IAR with potentially relevant lesions†15 (5.9%)8 (8.3%)4 (2.9%)3 (17.6%)
  • *Includes PDAC, PanIN3 and IPMN with high-grade dysplasia.

  • †Also includes multifocal PanIN2, BD-IPMN with low/moderate dysplasia±AFL and pNET.

  • AFL, atypical flat lesion; BD, branch duct; EUS, endoscopic ultrasonography; FPC, familial pancreatic cancer; IAR, individuals at risk; IPMN, intraductal papillary mucinous neoplasia; MRCP, MR cholangiopancreatography; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; pNET, pancreatic neuroendocrine tumour.